Abstract
An East Asian-specific variant on aldehyde dehydrogenase 2 (ALDH2 rs671, G>A) is the major genetic determinant of alcohol consumption. We performed an rs671 genotype-stratified genome-wide association study meta-analysis in up to 40,679 individuals from Japanese populations to uncover additional loci associated with alcohol consumption in an rs671-dependent manner. No loci satisfied the genome-wide significance threshold in wild-type homozygotes (GG), but six loci (ADH1B, ALDH1B1, ALDH1A1, ALDH2, GOT2, and MYOM1-MYL12A) did so in heterozygotes (GA). Of these, three loci (ALDH2, GOT2, and MYOM1-MYL12A) were novel, and two (ADH1B and ALDH1B1) showed genome-wide significant interaction with rs671. Our results identify a new genetic architecture associated with alcohol consumption, and shed additional light on the genetic characteristics of alcohol consumption among East Asians.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Cancer Center Research and Development Fund (28-A-19 and 31-A-18). The HERPACC Study was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, Culture and Technology of Japan Priority Areas of Cancer (17015018), Innovative Areas (221S0001), and JSPS KAKENHI Grants (JP16H06277 [CoBiA], JP26253041, JP20K10463) and Grant-in-Aid for the Third Term Comprehensive 10-year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare of Japan. Yamagiwa Yoshida Memorial UICC International Cancer Study Grants supported the initial component of the alcohol consumption GWAS within the HERPACC Study. The J-MICC Study was supported by Grants-in-Aid for Scientific Research for Priority Areas of Cancer (No. 17015018) and Innovative Areas (No. 221S0001) and by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant (No. 16H06277 [CoBiA]) from the Japanese Ministry of Education, Culture, Sports, Science and Technology. This work has also been supported in part by funding for the BioBank Japan Project from the Japan Agency for Medical Research and Development since April 2015, and the Ministry of Education, Culture, Sports, Science and Technology from April 2003 to March 2015. The JPHC Study was supported by the National Cancer Center Research and Development Fund (23-A-31 [toku], 26-A-2, 28-A-19, 29-A-4 and 31-A-18), the Practical Research for Innovative Cancer Control (JP16ck0106095 and JP19ck0106266) from the Japan Agency for Medical Research and Development, and a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan (from 1989 to 2010). The TMM Study was supported by grants from the Reconstruction Agency, from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), and from the Japan Agency for Medical Research and Development (AMED) [Grant no. JP20km0105001, JP20km0105002, JP20km0105003, and JP20km0105004]. The Nagahama Study was supported by JSPS, a Grant-in-Aid for Scientific Research (C), KAKENHI Grant Number JP17K07255 and JP17KT0125, and the Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and Development, AMED, under Grant Numbers JP16ek0109070h0003, JP18kk0205008h0003, JP18kk0205001s0703 JP19ek0109283h0003, and JP19ek0109348h0002. The funders had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review and approval of the article; or the decision to submit the article for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The HERPACC Study was approved by the Institutional Ethics Committee of Aichi Cancer Center, Nagoya, Japan. The J-MICC Study was approved by the ethics committee of Nagoya University Graduate School of Medicine (Approval No.: 2010-0939), Nagoya, Japan. The JPHC Study was approved by the institutional review board of the National Cancer Centre (Approval No.:2011-044), Tokyo, Japan. The TMM CommCohort Study was approved by the Institutional Review Boards of Iwate Medical University and Tohoku University. The Nagahama Study was approved by the ethics committee of Kyoto University Graduate School of Medicine and by Nagahama Municipal Review Board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of interest: The authors declare no potential conflicts of interest.
Data Availability
Data will be available when the manuscript is formally published in certain journal.